We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMelanie Grooms
Modified over 2 years ago
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma by Michele Cavo, Lucia Pantani, Maria Teresa Petrucci, Francesca Patriarca, Elena Zamagni, Daniela Donnarumma, Claudia Crippa, Mario Boccadoro, Giulia Perrone, Antonietta Falcone, Chiara Nozzoli, Renato Zambello, Luciano Masini, Anna Furlan, Annamaria Brioli, Daniele Derudas, Stelvio Ballanti, Maria Laura Dessanti, Valerio De Stefano, Angelo Michele Carella, Magda Marcatti, Andrea Nozza, Felicetto Ferrara, Vincenzo Callea, Catello Califano, Annalisa Pezzi, Anna Baraldi, Mariella Grasso, Pellegrino Musto, and Antonio Palumbo Blood Volume 120(1):9-19 July 5, 2012 ©2012 by American Society of Hematology
CONSORT diagram of patient flow through the study. Michele Cavo et al. Blood 2012;120:9-19 ©2012 by American Society of Hematology
Analysis of outcomes from the start of consolidation therapy with VTD or TD. Kaplan-Meier curves for TTP (A), PFS (B), and OS (C) from the landmark of starting consolidation therapy. *P value according to log-rank test. Michele Cavo et al. Blood 2012;120:9-19 ©2012 by American Society of Hematology
Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy. Michele Cavo et al. Blood 2012;120:9-19 ©2012 by American Society of Hematology
Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to the presence or absence of cytogenetic abnormalities. Michele Cavo et al. Blood 2012;120:9-19 ©2012 by American Society of Hematology
Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to t(4;14) positivity or negativity. Michele Cavo et al. Blood 2012;120:9-19 ©2012 by American Society of Hematology
The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional Yuxin Ding Department of Biostatistics 12/07/2015.
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) by Antonio Palumbo,
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation by Roberto.
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination by Giulia Benevolo,
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based.
Treatment For Newly Diagnosed Myeloma
Proteasome inhibitors in multiple myeloma: 10 years later Philippe Moreau, Paul G. Richardson, Michele Cavo, Robert Z. Orlowski, Jesu´s F. San Miguel,
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
1 ANCO ASH Highlights 2007: Multiple Myeloma Joseph M. Tuscano, MD University of California, Davis.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MM): Updated Results of a Multicenter Phase I/II Study After.
Ravi Vij MD Associate Professor Section of BMT and Leukemia
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing by Patrizia Leone, Simona.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs) by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach Joan Blade´, Carlos Ferna´ndez de.
Strategies for front-line treatment of Multiple Myeloma
Disclosures for Palumbo Antonio, MD
Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,
Facon T et al. Proc ASH 2013;Abstract 2.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Myeloma and Transplant
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ Multiple Myeloma: Is FISH passé? Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Should Alkylators be used Upfront in Transplant-Ineligible Patients? NO!! Lymphoma-Myeloma October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.
Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.
© 2017 SlidePlayer.com Inc. All rights reserved.